Evidence map›Paper›PMID 38294582›Full record

ArticleAngiogenesis2024

Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.

T Al Tabosh, H Liu, D Koça, M Al Tarrass, L Tu, S Giraud, L Delagrange, M Beaudoin, S Rivière, V Grobost and 12 more

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Angiogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05632484 (Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia), which is not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05632484 nacompletednot on this map

Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia

TypeinterventionalSponsorHospices Civils de LyonRan2023 to 2023Enrolled16ConditionsHereditary Haemorrhagic TelangiectasiaArmsCord blood sampling, Cord sampling
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Hereditary haemorrhagic telangiectasia.Nature reviews. Disease primers · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. YAP/TAZ drives Notch and angiogenesis mechanoregulation in silico.NPJ systems biology and applications · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 3 countries.

T Al TaboshBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0009-0006-7577-2904
H LiuBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0003-3830-3421
D KoçaBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0003-4838-3090
M Al TarrassBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0009-0003-9337-9100
L TuFaculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France.ORCID 0000-0003-2336-5099
S GiraudGenetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France.
L DelagrangeGenetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France.
M BeaudoinGenetics Department, Femme-Mère-Enfants Hospital, Hospices Civils de Lyon, 69677, Bron, France.
S RivièreInternal Medicine Department, CHU of Montpellier, St Eloi Hospital and Center of Clinical Investigation, INSERM, CIC 1411, 34295, Montpellier Cedex 7, France.
V GrobostInternal Medicine Department, CHU Estaing, 63100, Clermont-Ferrand, France.
M Rondeau-LutzInternal Medicine Department, University Hospital of Strasbourg, 67091, Strasbourg Cedex, France.ORCID 0000-0001-7977-1411
O DupuisHôpital Lyon SUD, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, 69100, Villeurbanne, France.
N RicardBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0002-7572-173X
E TilletBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0002-0076-8007
P MachillotBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0002-5640-929X
A SalomonBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0003-4425-6860
C PicartBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0003-0130-1000
C BattailBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0001-6849-7824
S Dupuis-GirodBiosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0002-8834-5526
C GuignabertFaculté de Médecine, Pulmonary Hypertension: Pathophysiology and Novel Therapies, Université Paris-Saclay, 94276, Le Kremlin-Bicêtre, France.ORCID 0000-0002-8545-4452
A Desroches-Castan *Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France.ORCID 0000-0002-3301-9504
S Bailly *Biosanté unit U1292, Grenoble Alpes University, INSERM, CEA, 38000, Grenoble, France. sabine.bailly@cea.fr.ORCID 0000-0003-1043-7030
Inserm · FRHôpital Femme Mère Enfant · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRUniversité Claude Bernard Lyon 1 · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterozygous activin receptor-like kinase 1 (ALK1) mutations are associated with two vascular diseases: hereditary hemorrhagic telangiectasia (HHT) and more rarely pulmonary arterial hypertension (PAH). Here, we aimed to understand the impact of ALK1 mutations on BMP9 and BMP10 transcriptomic responses in endothelial cells. Endothelial colony-forming cells (ECFCs) and microvascular endothelial cells (HMVECs) carrying loss of function ALK1 mutations were isolated from newborn HHT and adult PAH donors, respectively. RNA-sequencing was performed on each type of cells compared to controls following an 18 h stimulation with BMP9 or BMP10. In control ECFCs, BMP9 and BMP10 stimulations induced similar transcriptomic responses with around 800 differentially expressed genes (DEGs). ALK1-mutated ECFCs unexpectedly revealed highly similar transcriptomic profiles to controls, both at the baseline and upon stimulation, and normal activation of Smad1/5 that could not be explained by a compensation in cell-surface ALK1 level. Conversely, PAH HMVECs revealed strong transcriptional dysregulations compared to controls with > 1200 DEGs at the baseline. Consequently, because our study involved two variables, ALK1 genotype and BMP stimulation, we performed two-factor differential expression analysis and identified 44 BMP9-dysregulated genes in mutated HMVECs, but none in ECFCs. Yet, the impaired regulation of at least one hit, namely lunatic fringe (LFNG), was validated by RT-qPCR in three different ALK1-mutated endothelial models. In conclusion, ALK1 heterozygosity only modified the BMP9/BMP10 regulation of few genes, including LFNG involved in NOTCH signaling. Future studies will uncover whether dysregulations in such hits are enough to promote HHT/PAH pathogenesis, making them potential therapeutic targets, or if second hits are necessary.

Indexed as

Pulmonary Arterial HypertensionTelangiectasia, Hereditary HemorrhagicActivin Receptors, Type IIAdultBone Morphogenetic ProteinsEndothelial CellsGene Expression ProfilingGrowth Differentiation Factor 2HumansInfant, NewbornMutationActivin Receptors, Type IIBMP10 protein, humanBone Morphogenetic ProteinsGrowth Differentiation Factor 2ALK1BMPHHTLFNGPAHRNA-seq

Identifiers

PMID38294582
PMCPMC11021321
OpenAlexW4391420568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.